:
Pt-based drugs are widely used in clinics for the treatment of cancer. The mechanism of action of these molecules
rely on their interaction with DNA. However, the recognition of these metal compounds by proteins plays an important role
in defining pharmacokinetics, side effects and their overall pharmacological profiles. Single crystal X-ray diffraction studies
provided important information on the molecular mechanisms at the basis of this process. Here, the molecular structures of
representative adducts obtained upon reaction with proteins of selected Pt-based drugs, including cisplatin, carboplatin and
oxaliplatin, were briefly described and comparatively examined. Data indicate that metal ligands play a significant role in
driving the reaction of Pt compounds with proteins; non-covalent interactions that are formed in the early steps of Pt compound/protein recognition process play a crucial role in defining the structure of the final Pt-protein adduct. In the metalated
protein structures, Pt centers coordinate few protein side chains, such as His, Met, Cys, Asp, Glu and Lys residues upon releasing of labile ligands.